Vigil Neuroscience Reports Interim Data on Oral Therapy for Alzheimer’s
Vigil Neuroscience (NASDAQ: VIGL) announced interim data from its ongoing Phase 1 clinical trial of VG-3927, a once-daily oral therapy for Alzheimer’s disease (AD). The data from healthy volunteers supports continued development, showcasing the therapy’s safety, tolerability, and efficacy. VIGL shares traded up 11% midday on the news.
Key Highlights:
- VG-3927 exhibited a favorable safety profile, with all adverse events being mild or moderate and resolving without intervention. No serious adverse events were reported.
- VG-3927 demonstrated a significant decrease in sTREM2 in cerebrospinal fluid (CSF), indicating strong target engagement and potential efficacy for AD treatment.
- The therapy showed a predictable pharmacokinetic profile, supporting its potential as a once-daily oral treatment.
- Complete Phase 1 data, including results from an Alzheimer’s patient cohort, will be reported in Q1 2025. Additionally, new preclinical and clinical data will be presented at the 2024 Alzheimer’s Association International Conference (AAIC) in late July.
Ivana Magovčević-Liebisch, Ph.D., J.D., President and CEO of Vigil commented, “We are encouraged by these data which demonstrate that VG-3927 has the potential to become a differentiated approach to treating AD. With approximately 6.7 million Americans living with AD, there is a critical need for new therapies with improved safety and efficacy that can broadly address multiple aspects of AD disease pathophysiology.”
